万赛维的效果怎样？

Tablet (Valcyte), chemical name is (S)-2-amino-3-methylbutyric acid 2-[(2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl) methoxy]-3-hydroxypropyl ester hydrochloride, which is an oral anti-cytomegalovirus (CMV) developed by the Swiss company Roche As an infection drug, Valcyte is suitable for the treatment of patients with acquired immunodeficiency syndrome (AIDS) combined with cytomegalovirus (CMV) retinitis, and for the prevention of CMV infection in high-risk solid organ transplant patients. Human viruses that Valcyte is sensitive to include human cytomegalovirus (HCMV), and Valcyte is sensitive to herpes simplex virus-1 and herpes simplex virus-2 (HSV-1, HSV-2), human herpesvirus-6, 7, 8 (HHV-6, 7, 8), Epstein-Barr virus, varicella-zoster virus (VZV) and hepatitis B virus.

What is the effect of Vancevi?

The antiviral effect of Valcyte has been clinically confirmed by treating AIDS patients with newly diagnosed retinitis (clinical study WV15376). After 4 weeks of treatment with Valcyte, the detection rate of CMV virus decreased from 46% (32/69) to 7% (4/55). 

Clinical studies of Valcyte tablets in AIDS patients infected with CMV retinitis have shown that Valcyte tablets and intravenous ganciclovir are equally effective in the induction treatment of CMV retinitis. In the study, patients with newly diagnosed CMV retinitis were randomly assigned to the Valcyte tablet group or the intravenous ganciclovir group for induction therapy. The proportion of patients with progression of CMV retinitis at week 4 was the same in both groups. After induction therapy, both groups of patients in the study continued to receive maintenance therapy with Valcyte 900 mg per day. Among patients who received valganciclovir hydrochloride tablets or intravenous ganciclovir induction therapy followed by maintenance therapy with tablets (Valcyte), respectively, the mean (median) time from randomization to worsening of CMV retinitis was: 226 (160) days and 219 (125) days.